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*e capability of ﬂavonoids in sensitizing cancer cells was demonstrated in numerous works to chemotherapy and converse
multidrug resistance by modulating eﬄux pumps and apoptosis mechanisms. *ree ﬂavonoids, namely, bavachinin, tephrosin,
and candidone, have been recently introduced to cancer treatment research presenting various activities, such as antibacterial,
immunomodulatory, cell death, and anticancer. Less information exists regarding the therapeutic signiﬁcance of these ﬂavonoids
in cancer treatment, especially in overcoming multidrug resistance (MDR). Here, we tempted to investigate the potency of these
agents in reversing MDR by analyzing their eﬀects as chemosensitizers on cell cytotoxicity, P-gp and ABCG2 protein expression
levels, and their function on two multidrug-resistant cell lines, P-gp-overexpressing human gastric adenocarcinoma cell line
(EPG85.257RDB) and ABCG2-overexpressing human epithelial breast cancer cell line (MCF7/MX).*e inhibitory concentration
of 10% (IC10) of bavachinin, tephrosin, and candidone in EPG85.257RDB cells was 1588.7± 202.2, 264.8± 86.15, and
1338.6± 114.11 nM, respectively. Moreover, these values in MCF7/MX cell were 2406.4± 257.63, 38.8± 4.28, and 27.9± 5.59 nM,
respectively. Expression levels of ABCG2 and P-gp were not signiﬁcantly downregulated by these ﬂavonoids. Maximum levels of
daunorubicin and mitoxantrone accumulations and minimum rates of drug eﬄux in both cell lines were detected 48 hrs
posttreatment with tephrosin and bavachinin, respectively. Chemosensitization to mitoxantrone and daunorubicin treatments
was, respectively, achieved in MCF7/MX and EPG85.257RDB cells in response to IC10 of bavachinin and tephrosin, in-
dependently. *ese eﬀects did not follow time-dependent manner, and each ﬂavonoid had its cell-dependent patterns. Overall,
bavachinin, tephrosin, and candidone showed potency to sensitize MDR cells to daunorubicin and mitoxantrone and could be
considered as attractive MDR modulators for cancer treatment. However, their action was time and cell speciﬁc.
1. Introduction
A major problem in cancer chemotherapy is drug resistance,
not only to single, but to multiple drugs, which signiﬁcantly
compromises treatment outcomes. *is phenotype is known
as multidrug resistance (MDR), which is characterized by
reduced intracellular drug accumulation leading to treatment
failure. Variety of factors causes drug resistance; among them,
overexpression of ATP-binding cassette (ABC) transporters is
themost frequently occurring factor [1, 2]. So far, 49members
of human ABC transporter family have been discovered;
among them, P-glycoprotein (P-gp, also referred to ABCB1 or
MDR1) and ABCG2 (MXR or BCRP) which are the im-
portant members of ABC family attribute to MDR in cancer
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cells. *ese energy-dependent drug eﬄux transporters rec-
ognize and transport various chemotherapeutic agents out of
the cell and consequently decrease intracellular drug levels
and reduce their cytotoxic activity [3, 4]. *erefore, inhibiting
and even reversing MDR have been an important goal for
oncology researches [5, 6]. *e most characterized and the
ﬁrst described ABC transporter is P-glycoprotein, a widely
expressed protein with a broad spectrum of substrates and
known to be responsible for the development of chemo-
resistance in cancer cells.
Nevertheless, ABC transporters are attracting interest as
key players in carcinogenesis, and their activity often cor-
relates with cancer progression and aggressiveness. As an
example, P-gp is the best characterized multidrug resistance
(MDR) protein, being the ﬁrst human ABC transporters to
be cloned. P-gp is known to transport a variety of hydro-
phobic drugs outside the cancer cells, thus conferring
chemoresistance to numerous tumor types, such as gastric
adenocarcinoma, breast cancer, pancreatic cancer, lung
cancer, hepatocellular carcinoma, and neuroblastoma,
leading to treatment failure and consequent tumor relapse.
*e P-gp expression has been associated with tumor
phenotype in colorectal cancer and soft tissue sarcomas, and
its overexpression has also been linked with the progression
of lymph nodemetastases. P-gp expression was also reported
to be induced and elevated in chemoresistant breast and
ovarian cancers. Furthermore, P-gp is involved in the re-
sistance to apoptosis, which is one of the hallmarks of cancer
cells. Inhibition of P-gp transporter results in cell cycle arrest
and induction of apoptosis in leukemia and colon cancer,
whereas its overexpression leads to cells being less re-
sponsive to apoptotic stimuli.
ABCG2 is known as breast cancer resistance protein
(BCRP) and plays a role in multidrug resistance. Never-
theless, ABCG2 is mostly known for its role in multidrug
resistance, being ﬁrst described as breast cancer resistance
protein or BCRP. ABCG2 is found to be overexpressed in
numerous drug-resistant cancers including breast, ovarian,
liver, lung, and melanoma, and it correlates with poor
prognosis. Also, ABCG2 is found to be particularly over-
expressed in a subpopulation of slow-cycling cancer stem-
like cells with self-renewal capacity and high chemo-
resistance [7].
Various studies have recently demonstrated the capability
of phytochemicals, such as ﬂavonoids, to boost the cancer
cells sensitivity to anticancer medications and inverse MDR
through inhibiting ABC transporters [8]. Flavonoids, which
are widely present in plants, may enhance the eﬀectiveness of
common cancer chemotherapy via preservative or synergistic
impacts or by prompting chemosensitization in cancer cells.
Moreover, cancer therapy-induced toxicity can be diminished
by ﬂavonoids while decreasing the threat of deleterious,
unwanted complications of chemotherapeutic agents [9, 10].
*ese ﬂavonoids exert their eﬀects through various mecha-
nisms, including inhibition of eﬄux pumps, cell death acti-
vation, and cell cycle arrest [11]. Lately, three ﬂavonoids,
namely, bavachinin [12], candidone [13], and tephrosin [14],
have been introduced to cancer treatment research. Bava-
chinin is a ﬂavonoid obtained from the seeds of Psoralea
corylifolia Linn that displays various activities, including
antiangiogenic, antitumor [15], antibacterial [16], antiallergic,
and anti-inﬂammatory activities [17, 18]. Moreover, candi-
done, which is obtained from the stems and leaves of
Tephrosia candida [19], exhibits antitumor [13] and anti-
bacterial activities [20]. Tephrosin is isolated from Amorpha
fruticosa (Leguminosae) and has inhibitory eﬀects on human
colorectal adenocarcinoma cell line [21], cancer cells invasion
[22], and nuclear factor-kB activity [23].
*is study aimed at ﬁnding the eﬀects of bavachinin,
candidone, and tephrosin, as chemosensitizer, against ER-
positive (estrogen receptor-positive) and PR-positive (pro-
gesterone receptor-positive) mitoxantrone (MX) resistant
type of breast cancer cell line, MCF-7/MX, and the classical
MDR cell line of gastric carcinoma resistant to daunoru-
bicin, EPG 85.257 RDB cells. MCF-7/MX and EPG 85.257
RDB cells present the MDR phenotype, which is charac-
terized by high expression levels of ABCG2 and P-gp
transporters [24, 25]. *erefore, the impacts of these ﬂa-
vonoids were assessed in the current work on protein ex-
pression levels and activity of ABCG2 and P-gp transporters.
*e chemical structure of these ﬂavonoids is given in
Scheme 1.
2. Materials and Methods
2.1. Media and Chemicals. Trypsin, streptomycin and pen-
icillin, RPMI-1640 medium (containing L-glutamine and
high glucose), and fetal bovine serum (FBS) were prepared
from Gibco (Grand Island, NY, USA). Chemotherapeutic
agents (daunorubicin and mitoxantrone), thiazolyl blue
tetrazolium bromide (MTT), Tween-20, phosphate-buﬀered
saline tablet (PBS), bovine serum albumin (BSA), bava-
chinin, candidone, tephrosin, and MDR pump inhibitors
(novobiocin sodium salt and verapamil hydrochloride) were
bought from Sigma-Aldrich (Deisenhofen, Germany). P-gp
and ABCG2 primary antibodies (mouse anti-P glycoprotein
and anti-BCRP/ABCG2 monoclonal IgG, Abcam), anti-
mouse secondary IgG1 of goat and FITC-conjugated IgG2a,
and the suitable isotype controls were prepared from Abcam
(Cambridge, USA). DMSO (dimethyl sulfoxide) was used to
prepare the stocks of ﬂavonoids and drugs, but to prepare
diﬀerent concentrations at the time of the experiment, a
whole culture medium was used. DMSO, methanol, form-
aldehyde, and the other analytical-grade chemicals and
solvents were obtained by Merck (Darmstadt, Germany).
2.2. Culturing the Cells and Cell Lines. P-gp-overexpressing
human gastric adenocarcinoma cell line (EPG85.257RDB)
and ABCG2-overexpressing epithelial breast cancer cell line
of the human (MCF7/MX) were kindly oﬀered by Professor
Herman Lage (Medical University of Berlin, Charite Campus
Mitte, Berlin, Deutschland). *e cells were cultured in RPMI-
1640 medium supplemented with 10% (v/v) FBS, antibiotics
(100 μ/mL penicillin and 100 μ/mL streptomycin), and 2mM
L-glutamine. *e cultured cells were incubated at the tem-
perature of 37°C in a moistened atmosphere involving 5%
CO2. Moreover, the culture media of the RDB and MX-
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resistant cell lines were supplemented with 100 nM mitox-
antrone or 4.74 μM daunorubicin, respectively [26, 27].
2.3. In Vitro Cytotoxicity Assessment. Cells were planted in
96-well plates at a density of 1,000 cells per well and were
incubated at 37°C for 24 hrs. *e cells were then treated with
serial dilutions (0–15000 nM) of bavachinin, candidone, and
tephrosin. In vitro cytotoxicity was measured following
incubation for ﬁve days of the treated cells through MTT
assay (at 570 nm) and via a BioTek microplate reader
(ELX800™, USA). Inhibitory concentrations of 10% (IC10)
are determined as the drug concentrations, decreasing the
survival rates of the cells seeded in the wells to 10% in
comparison with the control that was untreated cells. IC10
values were computed from the most optimal regression
design of the proportion practicability versus the applied
concentrations of each drug [27].
2.4. Flow Cytometry Analysis of Relative MDR Pump Levels.
Resistant cancer cells were planted in 6-well tissue culture
plates at a density of 5×105 cells/well and were incubated at
the temperature of 37°C. *e culture media for MX- and
RDB-resistant cell lines were supplemented with 100 nM
mitoxantrone and 4.74 μM daunorubicin, correspondingly
[26, 27]. *e cells were cultured in a medium without the
drug for at least seven days before the experiments.*en, the
cells were individually treated with IC10 of bavachinin,
candidone, and tephrosin for 24, 48, and 72 hrs in 6-well
plates. Afterward, the cells were gathered by trypsinization,
ﬁxed, and permeabilized by 10% (v/v) formaldehyde and
90% (v/v) ice-cold methanol for 10min, respectively.
*rough incubating the cells in PBS, including 10%
(w/v) bovine serum albumin (BSA), nonexplicit binding
sites were blocked for 1 hr at room temperature. *e
samples were then treated with each of P-gp (0.1 mg/ml)
and ABCG2 (0.25mg/ml, Abcam) monoclonal antibodies
diluted (0.01 v/v) in PBS containing 2% BSA and 0.01%
Tween-20 at 4°C. After that, the cells were incubated with
the equivalent FITC-conjugated anti-mouse secondary
immunoglobulin of goat (2 mg/ml) diluted (0.01 v/v) in
PBS with 0.01% Tween-20 and 2% BSA within 20min on
ice in the dark. Rinsing with PBS at room temperature was
performed two times within all the phases. Utilizing a BD
FACSCalibur™ ﬂow cytometer (BD Biosciences, USA)
along with appropriate negative controls (secondary an-
tibody, autoﬂuorescence, and isotype controls), the protein
levels of P-gp and ABCG2 were analyzed to diminish the
nonprecise background signals. To perform the analysis,
intact cells were separated from cellular clumps and cellular
debris utilizing forward/side scatter gating. FITC-labeled
proteins were excited using a regular argon laser at 488 nm,
and via a 530/30 nm band-pass ﬁlter (FL1), the emission
ﬂuorescence strength was recorded. *e obtained results
were ﬁnally treated and analyzed via WinMDI (V.2.8) and
FlowJo (version 7.6.1) in comparison with the corre-
sponding untreated controls [27, 28].
2.5. Eﬀects of Flavonoids on Kinetic of Chemotherapeutics
Accumulation and Eﬄux. *e impacts of ﬂavonoids on the
functionality of the MDR pump were quantiﬁed using ﬂow
cytometry. Concisely, the cells were planted in 6-well plates
at a density of 5×105/well and were individually treated
using IC10 of bavachinin, candidone, and tephrosin for 24,
48, and 72 hrs. *e cells were collected by trypsinization and
equally allocated into two separate groups which were
treated with ﬂuorescent chemotherapeutic substrates,
namely, daunorubicin and mitoxantrone (1 μM for P-gp and
3 μM for ABCG2 eﬄux pumps, respectively), individually or
combined with explicit pump inhibitors, namely, verapamil
(10 μM for P-gp) and novobiocin (200 μM for ABCG2).
*en, the cells were incubated for 30min at 37°C, after being
gathered at 800 ×g and rinsed two times via ice-cold PBS.
*e suspended cells were correspondingly allocated into two
parts; one half was incubated on ice in the dark and FACS
analysis was immediately performed to investigate the ac-
cumulation kinetics, while the other half was treated using
RPMI-1640 including 10% FBS supplemented with in-
hibitors (cells treated with inhibitor in the accumulation
phases) or with no precise inhibitors (cells treated without
inhibitor in the accumulation phases) for 1 hr at 37°C and
was rinsed two times with ice-cold PBS.*en, FACS analyses
were performed on these cells to study eﬄux kinetics.
To remove cell clumps and cellular debris, forward/side
scatter gating was utilized. *e cells were excited at 488 nm
while recording the emission via a 585/42 nm band-pass
ﬁlter (FL2, for daunorubicin) and a 670 nm long-pass ﬁlter
(FL3, for mitoxantrone-treated cells). A total of 105 hap-
penings were recorded for each sample, and mathematical
procedures were performed using equations (1) and (2).
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Modulator, MFI, specimen, and control are the pump in-
hibitors, mean ﬂuorescent strength, ﬂavonoid-treated cells,
and untreated cells, respectively. All the experiments were
performed in triplicate, and untreated cells were considered
as the negative controls [27].
Δefflux � MFI
(withmodulator specimen)
− MFI
(withoutmodulator specimen)
( )(÷ MFI
(withmodulator control)
− MFI
(withoutmodulator control)
( )) × 100%,
(1)
drug accumulation � MFI
(withoutmodulator specimen)
÷ MFI
(withoutmodulator control)
( ) × 100%. (2)
2.6. Statistical Analysis. Statistical analyses were carried
out by GraphPad Prism 6 software (GraphPad Software.
San Diego, CA). *e ﬁndings were provided as the
mean ± standard deviation. One-way ANOVA with post
hoc Dunnett test was utilized to compare the results
within the groups. P values less than 0.05 were regarded as
statistically signiﬁcant. All the tests were carried out at
least in triplicate.
3. Results
3.1. In Vitro Cytotoxicity of Flavonoids. Using MTT assay,
the IC10 of bavachinin, candidone, and tephrosin on
MDR-resistant lines was determined (MCF7/MX and
EPG85.257RD). For this goal, after treatment with serial
dilutions of the abovementioned ﬂavonoids for ﬁve days,
cytotoxicity values of each ﬂavonoid were determined
using a dose-response curve based on the obtained data.
*e IC10 values of the triplicate experiments were re-
ported as the mean ± SE in Table 1. Tephrosin and can-
didone presented higher toxicity in MCF-7/MX than in
EPG85.257RDB cells.
3.2. Relative Protein Quantiﬁcation of MDR Pump. *e
relative protein expression levels of P-gp and ABCG2 with
and without IC10 of bavachinin, candidone, and tephrosin
were assessed using ﬂow cytometry. Figure 1(a) illustrates
the eﬀect of bavachinin, candidone, and tephrosin on the
protein expression level of ABCG2 in MCF7/MX cell line,
and Figure 1(b) displays the impact of the abovementioned
ﬂavonoids on the expression level of P-gp protein in
EPG85.257RDB cell line. According to Figure 1, the protein
expression levels of ABCG2 and P-gp were not signiﬁcantly
downregulated by the studied ﬂavonoids (P> 0.05). Can-
didone in MCF7/MX cells and tephrosin in both
EPG85.257RDB and MCF7/MX cells signiﬁcantly upregu-
lated the expression levels of ABCG2 and P-gp proteins.
3.3. Eﬀect of Flavonoids on MDR Transporter Activity.
Following assessing the cytotoxicity and IC10 of the studied
ﬂavonoids, the modality of the eﬀects of these ﬂavonoids on
mitoxantrone and daunorubicin accumulation in MCF7/
MX (Figure 2(a)) and EPG85.257RDB cells was evaluated
(Figure 2(b)). Eﬄux of mitoxantrone from MCF7/MX cells
was considerably decreased by bavachinin in a time-de-
pendent mode without any alteration in its accumulation.
Treatment of MCF7/MX cells with tephrosin for 48 hrs
resulted in the maximum accumulation of mitoxantrone.
However, this maximum accumulated amount of mitox-
antrone was signiﬁcantly decreased after 72 hrs of tephrosin
treatment. Eﬄux of mitoxantrone fromMCF7/MX cells and
its accumulation were signiﬁcantly increased following
72 hrs of treatment with candidone.
Accumulation of daunorubicin in EPG85.257RDB cells
was signiﬁcantly enhanced during the ﬁrst 24 hrs of ex-
posure to candidone (P< 0.001). Daunorubicin eﬄux from
EPG85.257RDB cells was signiﬁcantly decreased by can-
didone after 48 hrs of treatment without any alteration
in its accumulation level (P< 0.0001). Although 72 hrs
of treatment of the cells with tephrosin resulted in an
increase in the accumulated amount of daunorubicin
(P< 0.01), themaximumaccumulation level of daunorubicin in
EPG85.257RDB cells was observed after 48hrs of tephrosin
exposure (P< 0.0001). An appropriate time-dependent manner
in accumulation of daunorubicin in the cells could not be
detected in this study. Interestingly, both bavachinin and
tephrosin signiﬁcantly reduced the activity of P-gp pump in
EPG85.257RDB cell line. However, only a 48hrs treatment with
tephrosin could result in a decreased eﬄux and an increased
accumulation of daunorubicin up to the maximum rate in
EPG85.257RDB cells (P< 0.0001). Even though the treatment
of the cells with bavachinin did not considerably alter the ac-
cumulation of daunorubicin and mitoxantrone in both the
abovementioned cell lines, theminimum level of drug eﬄuxwas
detected 48hrs after bavachinin exposure.
4. Discussion
MDR transporters are involved in cross-resistance against
structurally and functionally diﬀerent anticancer agents,
which results in chemotherapy failure. Daunorubicin and
mitoxantrone are commonly used chemotherapeutic agents
for the treatment of advanced human cancers. However,
their long-term administration leads to drug resistance.
*erefore, vast eﬀorts have been made to search for new
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substances that eectively modulate drug resistance by
targeting eux pumps. ere is ample evidence that a-
vonoids could protect us from cancer (chemopreventive) or
enhance the anticancer eects of chemotherapy (chemo-
sensitizers) or even ght against cancer [29]. e strategy of
combining chemotherapeutic agents with avonoids to re-
verse MDR is a promising alternative for reaching higher
curability with lower toxicity. ree avonoids, namely,
bavachinin [12], candidone [13], and tephrosin [14], have
been recently introduced to cancer treatment research. In
this study, breast cancer (MCF7/MX) and gastric adeno-
carcinoma (EPG85.257RDB) resistant cell lines were ap-
plied, to investigate the eect of these avonoids uponMDR.
Overall, bavachinin, tephrosin, and candidone showed po-
tency to sensitize MDR cells to daunorubicin and mitox-
antrone. Moreover, their action is time and cell specic.
Despite the constant protein expression of ABCG2 and
P-gp in bavachinin-treated cells, eux of mitoxantrone
from MCF7/MX cells was signicantly reduced by this
avonoid (Figure 2(a)). However, this eect in daunoru-
bicin was limited to 24 and 48 hrs posttreatment in
EPG85.257RDB cells (Figure 2(b)). Recent studies have
reported various activities and properties for bavachinin,
including inhibition of nitric oxide production [30], pan
PPARs (peroxisome proliferator-activated receptors)
agonist [31], antiangiogenic, antitumor [15], antibacterial
[16], antiallergic, and anti-inammatory activities [17, 18].
Few studies have investigated the antitumor mechanism of
bavachinin. Nepal et al. (2012) have conducted a study to
investigate the angiogenesis eect of bavachinin both in
vitro and in vivo. eir results indicated that bavachinin
induced antiangiogenic and antitumor eects by targeting
hypoxia-inducible factor-1a [15]. However, the potential of
clinical application of bavachinin may be limited due to its
low water solubility (<30 ng/mL), rapid clearance, toxicity,
and subsequent liver injury [32, 33]. e toxicity of
bavachinin is partly induced by the oxidative damage
through p38/JNK MAPK (Jun N-terminal kinase and p38
mitogen-activated protein kinase) pathways [33] and po-
tent inhibitory eects against human UDP-glucuronosyl-
transferase 1A1 [34]. erefore, an alternative delivery
method should be developed to achieve eective treatment
[32].
e protein expression level of ABCG2 was signicantly
upregulated in the candidone-treated MCF7/MX cells
(Figure 1(a)), which was followed by an increase in
mitoxantrone eux (Figure 2(a)). In EPG85.257RDB cells,
although candidone decreased daunorubicin eux after
48 hrs, regardless of the P-gp protein expression and dau-
norubicin accumulation, and increased eux after 72 hrs
Table 1: IC10 values of bavachinin, candidone, and tephrosin for resistant cells.
Cell line Bavachinin Tephrosin Candidone
EPG85.257RDB 1588.7± 202.2 264.8± 86.15 1338.6± 114.11
MCF7/MX 2406.4± 257.63 38.8± 4.28 27.9± 5.59
e values are expressed as avonoids IC10± SE (nM).
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Figure 1: Relative quantication of MDR protein expression levels by ow cytometer. e protein levels of ABCG2 and P-gp in MCF7/MX
and EPG85.257RDB were, respectively, quantied in the presence of bavachinin, candidone, and tephrosin using ow cytometry. Fold
changes were calculated relative to the untreated control, and the data are presented as the mean of triplicate experiments± SEM. e
symbols ∗, ∗∗, and ∗∗∗ represent P values <0.05, <0.01, and <0.001, respectively. e Y-axis was plotted by log10 (a) and log2 (b).
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(Figure 2(b)). Few studies that have investigated the eﬀects
of candidone have reported weak antitumor [13] and
moderate antibacterial activities for this compound [20].
In contrast to candidone, tephrosin signiﬁcantly increased
P-gp protein expression level in EPG85.257RDB cells
(Figure 1(b)), and interestingly, augmented daunorubicin
accumulation and decreased eﬄux after 48 hrs treatment
(Figure 2(b)). Tephrosin did not aﬀect ABCG2 protein
expression while it increased mitoxantrone accumulation
after 48 hrs. However, the protein expression level of
ABCG2 in MCF7/MX cells was relatively upregulated
72 hrs after tephrosin treatment (Figure 1(a)). Moreover,
tephrosin treatment decreased mitoxantrone accumulation
(Figure 2(a)). Tephrosin, as an anticancer agent [22], pre-
vents cancer growth in human colorectal adenocarcinoma
cells [21], inhibits cancer cells invasion, induces diﬀerenti-
ation activity in leukemic cells [22], and inhibits the activity
of nuclear factor-kB [23]. Anticancer activity of tephrosin
may be implemented through the induction of epidermal
growth factor receptor (EGFR) and ErbB2 internalization
and degradation of colon cancer cells [35] as well as auto-
phagic cell death [36]. *erefore, the combination of this
agent with 2-deoxy-D-glucose (2-DG), a synthetic glucose
analog acting as a glycolytic inhibitor, intensiﬁes therapeutic
eﬃcacy of 2-DG by increasing the speed of ATP depletion
and blunting autophagy [37].
In conclusion, based on the ﬁndings of the current
work, ABCG2-overexpressing MCF7/MX cells and P-gp-
overexpressing EPG85.257RDB cells potently became
chemosensitizer to mitoxantrone and daunorubicin, after a
5-day treatment with bavachinin, tephrosin, and candidone
ﬂavonoids. Maximum daunorubicin and mitoxantrone
accumulation levels and minimum levels of drug eﬄux in
both cell lines were detected 48 hrs posttreatment with
tephrosin and bavachinin, respectively. *e eﬀects of the
studied ﬂavonoids did not follow a time-dependent
manner, and each ﬂavonoid had its cell-dependent patterns.
Also, there was no signiﬁcant balance between the reduced
eﬄux and increased accumulation responses in most of the
treatment groups. *ese results indicated that bavachinin,
candidone, and tephrosin could be considered as attractive
candidates of MDR modulators for multidrug-resistant
cancer treatment. However, further studies are required to
ﬁnd their toxicity levels, suitable delivery methods, and
mechanism of actions.
Consequently, ﬂavonoids are present in a variety of plant
foods, and they have few side eﬀects. On the other hand,
their anticancer and cancer prevention eﬀects have proven.
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Figure 2: Eﬀects of bavachinin, candidone, and tephrosin on the eﬄux of daunorubicin and mitoxantrone from MDR-resistant cells and
their accumulation. MCF7/MX (a) and EPG85.257RDB (b) cells were treated with IC10 of ﬂavonoids for 24, 48, and 72 hrs. *e data are
presented as the mean of triplicate experiments± SEM.*e symbols ∗, ∗∗, ∗∗∗, and ∗∗∗∗ represent P values <0.05, <0.01, <0.001, and <0.0001,
respectively. *e Y-axis was plotted by log10 (a, 24 h).
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With the results of this study, as well as future comple-
mentary studies, one of these ﬂavonoids, or a combination of
them, can be used as a MDR modulator, for enhancing the
therapeutic eﬃcacy of anticancer drugs.
However, in vivo studies and investigations into the
eﬀects of ﬂavonoids on the human body, as main challenges,
are still unclear.
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